Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898453 | 1.00 | HTR2A (0.57) | HTR2AHTR2CKCNH2PROKR1AHR | |
| SCHEMBL10067383 | 0.84 | AHR (0.50) | PROKR1AHRBRD3 | |
| SCHEMBL10067382 | 0.83 | AHR (0.48) | PROKR1AHRBRD3 | |
| SCHEMBL18503045 | 0.79 | HTR2A (0.72) | HTR2AHTR2CKCNH2AHRCCNT1 | |
| SCHEMBL2789206 | 0.79 | HTR2A (0.53) | HTR2AHTR2CKCNH2CCNT1CCNK | |
| SCHEMBL7897980 | 0.79 | HTR6 (0.46) | HTR2AHTR2CPARP1 | |
| SCHEMBL7904064 | 0.78 | HTR2A (0.40) | HTR2AHTR2CKCNH2CCNT1CCNK | |
| SCHEMBL26837562 | 0.77 | HTR2A (0.51) | HTR2AHTR2CKCNH2MAOADRD2 | |
| SCHEMBL10516888 | 0.75 | HTR2A (0.52) | HTR2AHTR2CKCNH2PARP1 | |
| SCHEMBL2790573 | 0.72 | EGFR (0.54) | HTR2AHTR2CKCNH2BRD3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074385-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3074385-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
| EP-3074385-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015079224-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015079224-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | GRIN2C, GRIN2A, PNMT | HTR2A 60/4885HTR2C 65/4885KCNH2 341/4885 |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | GRIN2C, GRIN2A, PNMT | HTR2A 60/4885HTR2C 65/4885KCNH2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.